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ETV6 is an ETS family transcriptional repressor for which head-to-tail polymerization of its PNT 
domain facilitates cooperative binding to DNA by its ETS domain. Chromosomal translocations 
frequently fuse the ETV6 PNT domain to one of several protein tyrosine kinases. The resulting 
chimeric oncoproteins undergo ligand-independent self-association, autophosphorylation, and 
aberrant stimulation of downstream signaling pathways leading to a variety of cancers. Currently, 
no small molecules inhibitors of ETV6 PNT domain polymerization are known and no assays 
targeting PNT domain polymerization have been described. In this study, we developed 
complementary experimental and computational approaches for identifying such inhibitory 
compounds. One mammalian cellular approach utilized a mutant PNT domain heterodimer system 
covalently attached to split Gaussia luciferase fragments. In this protein fragment 
complementation assay, inhibition of PNT domain heterodimerization reduces luminescence. A 
yeast assay took advantage of activation of the reporter HIS3 gene upon heterodimerization of 
mutant PNT domains fused to DNA-binding and transactivation domains. In this two-hybrid 
screen, inhibition of PNT domain heterodimerization prevents cell growth in medium lacking 
histidine. The Bristol University Docking Engine (BUDE) was used to identify virtual ligands 
from the ZINC8 library predicted to bind the PNT domain polymerization interfaces. Over 75 hits 
from these three assays were tested by NMR spectroscopy for binding to the purified ETV6 PNT 
domain. Although none were found to bind, lessons learned from this study may facilitate future 
approaches for developing therapeutics that act against ETV6 oncoproteins by disrupting PNT 




The ETV6 gene, known also as TEL (translocation ETS leukemia), encodes an ETS (E26 
transformation specific) family transcriptional repressor with roles in embryonic development and 
hematopoietic regulation.1,2,3 This gene is frequently rearranged in chromosomal translocations to 
form fusion oncoproteins linked with various cancers including leukemias, lymphomas, 
carcinomas, and sarcomas.4–6 Over 40 different such translocations are known to exist, including 
those leading to the ETV6-PDGFRB, ETV6-NTRK3, ETV6-ABL1/2, and ETV6-JAK2 gene 
fusions.4,6–9  
ETV6 is a modular protein composed of an N-terminal self-associating PNT (pointed, or 
SAM, sterile alpha motif) domain, a disordered central region reported to interact with co-
repressors, and a C-terminal DNA-binding ETS domain.10,11 Most of the oncogenic ETV6 
translocations lead to chimeras with the PNT domain fused to the protein tyrosine kinase (PTK) 
domain from a receptor tyrosine kinase. Crucial to their oncogenic properties is the propensity of 
the ETV6 PNT domain to tightly self-associate into an open-ended, left-handed helical polymer 
via head-to-tail binding of two relatively flat, hydrophobic interfaces.12–14 PNT domain 
polymerization enables ligand-independent autophosphorylation and activation of the PTK 
domain. This stimulates downstream cellular pathways, such as the PI3K/Akt and Ras-MAPK 
signaling cascades, and ultimately causes cellular transformation.15–17  
One well-characterized ETV6 translocation encodes the PNT domain fused to the PTK 
domain of neurotrophin tyrosine receptor kinase-3 (NTRK3). The resulting protein, named EN 
(ETV6-NTRK3), displays oncogenic properties including phenotypic transformation and soft agar 
colony formation of several experimental cell lines, as well as tumor formation in nude mice.6,17 
The ETV6 PNT domain polymerization interfaces, called the mid-loop (ML) and end-helix (EH) 
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surfaces, have hydrophobic cores surrounded by charged residues.18 The mutation of one of two 
key hydrophobic residues to a charged residue (A93D on the ML surface, or V112E or V112R on 
the EH surface, according to the human ETV6 numbering) disrupts polymerization.14,18 
Introduction of these mutations into EN expressing cell lines prevents EN polymerization, PTK 
activation and cellular transformation.13 Similarly, mutation of the K99-D101 charge pair bridging 
the PNT domain interfaces weakens polymerization and inhibits the transformation activity of EN 
in NIH3T3 cells.19 Co-expression of an isolated PNT domain also has a dominant negative effect, 
preventing cellular transformation.13 Together, these studies indicate inhibition of PNT domain 
polymerization as a viable therapeutic strategy against cancers driven by ETV6 chromosomal 
translocations. 
We hypothesized that small molecules that prevent the self-association, and hence 
oncogenic properties, of ETV6 chimeras containing the PNT domain might serve as a potential 
broad spectrum therapy against many ETV6 PNT domain-containing oncoproteins and avoid 
toxicities associated with perturbing the normal activities of receptor PTKs. Furthermore, although 
approximately one-third of the 28 ETS transcription factor family members in humans possess a 
PNT domain, only ETV6 and perhaps closely related ETV7 polymerize.20–22 Thus a molecule that 
selectively inhibits ETV6 PNT domain polymerization may have few side effects.  
Protein-protein interactions (PPIs) are challenging to disrupt, and hence we undertook 
complementary cellular and virtual screening strategies in the attempt to discover inhibitors of 
ETV6 PNT domain polymerization. Central to our approach is the use of PNT domains with 
monomerizing mutations in the EH or ML surfaces that can still associate with low nM affinity 
through their remaining complementary wild-type interfaces.14,18 The soluble "heterodimer" serves 
as a model of the insoluble polymer, opening the door for in vitro and in vivo screens. In brief, 
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both a mammalian cell-based assay utilizing a protein-fragment complementation approach with 
split Gaussia luciferase23 (Fig. 1A) and a yeast two-hybrid assay24 (Fig. 1B) were developed and 
used to screen chemical libraries for potential inhibitors. In parallel, large scale virtual screening 
using the Bristol University Docking Engine (BUDE) was performed to identify theoretical 
compounds that might bind to the PNT domain polymerization interfaces.25,26 Subsequently, 
candidate compounds were tested for inhibitory effects in cellular assays and for binding to the 
isolated ETV6 PNT domain as monitored by nuclear magnetic resonance (NMR) spectroscopy. 
Although no inhibitory compounds were successfully identified, the development, validation and 
implementation of these assays will be discussed herein.  
 
Materials and Methods  
Chemicals for Screening 
Screening compounds for the cellular assays consisted of 16,000 compounds from the 
Maybridge Hitfinder collection, 10,000 compounds from the ChemBridge DIVERset collection, 
1,120 compounds from Prestwick Chemicals, 1,280 compounds from the Sigma LOPAC library, 
2,000 compounds from the Microsource Spectrum collection, 2,697 compounds from the Selleck 
L1700 Bioactive Compound library, and 500 compounds from Biomol. The compounds were 
stored in 96-well plates at -25 °C as 5 mM stock solutions in DMSO. In addition, a small molecule 
library targeting PPIs consisting of 1,534 compounds was provided by the Perturbation of Protein-
Protein Interactions (PoPPI) collaborative program (UK). Candidate compounds from the BUDE 




Vectors and Cloning for the Split Luciferase Protein-fragment Complementation Assay 
The split luciferase protein-fragment complementation assay (PCA) was based on the 
protocol of Michnick and co-workers.23 Sequences encoding ETV643-125 (residues 43-125 of 
human ETV6, encompassing the PNT domain; Genbank Gene ID: 2120) with either an A93D or 
V112E substitution were cloned into either the modified mammalian expression vector 
pcDNA3.1/Zeo(+) or pcDNA3.1/Neo(+) at the 5’-end of sequences for humanized Gaussian 
Luciferase (hGLuc) fragments (Supplemental Table S1). The resulting constructs encoded either 
A93D- or V112E-PNT domain, a (GGGGS)2 flexible linker and either hGLuc(1)1-93 or hGLuc(2)94-
196. The latter are described herein as N-Luc or C-Luc, respectively. A control set of plasmids 
containing leucine zippers as the dimerization domains were also provided by Dr. Michnick.23 
 
Mammalian Cell Culture 
Human embryonic kidney cells 293 (HEK293, ATCC) cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM; Gibco) supplemented with 10% fetal bovine serum (FBS; 
Sigma) and 1% antibiotic-antimycotic (Gibco). Unless otherwise noted, this medium was used in 
all experiments. Stably expressing transformants were treated additionally with either or both 400 
µg/mL G418 (Gibco) and 50 µg/mL zeocin (Invitrogen). Cells were incubated at 37 °C with 5% 
CO2, and passaged upon reaching approximately 75-85% confluency. 
 
Transient Expression for Validation of the PCA 
HEK293 cells were seeded in 96-well clear bottom black microplates (Corning #6005182) 
at 15,000 cells/well and incubated at 37 °C. After 24 h, the medium was aspirated and 100 µL of 
fresh medium added. For transfection of a single species of DNA, 20 ng/µL of plasmid was added 
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to OPTIMEM (Gibco), and for transfection of two species of DNA, 10 ng/µL of each plasmid was 
added to OPTIMEM. Lipofectamine 2000 (Invitrogen) was diluted to 8% in OPTIMEM and added 
to the DNA at a 1:1 v:v ratio and incubated for 5 min at room temperature. After incubation, 10 
µL of the total prepared DNA, OPTIMEM and Lipofectamine 2000 were added to each well. Cells 
were incubated at 37 °C for either 24, 48 or 72 h. Prior to the luminescence reading, 50 µL of cell 
medium was removed and an equal volume of NanoFuel GLOW Assay (Nanolight Technology) 
for Gaussia luciferase was then added to each well. After incubation in the dark at ambient 
temperature for 5 min, the luminescence output was read for one second with a Varioskan LUX 
multimode microplate reader.  
 
Establishment of a Stably Expressing PNT Domain PCA System 
HEK293 cells were seeded in 6-well microplates at 400,000 cells/well and grown overnight 
to approximately 80% confluence. Cell medium was changed and the cells were transfected with 
Lipofectamine 2000 utilizing 25 ng/µL DNA for single plasmid transfections or 12.5 ng/µL DNA 
for each plasmid in a double plasmid transfection. After 24 h, the medium was aspirated, fresh 
medium was added and the cells were incubated again overnight. After 48 h, selection was 
introduced by incubating cells with medium supplemented with the corresponding antibiotic(s), 
replacing medium every 2-3 days, and splitting cells when 80% confluency was achieved. The 
resulting stable transformants were stored in liquid nitrogen.  
 
High-throughput PCA Screening 
For screening, stable transformants of A93D-PNT/N-Luc(Neo) and V112E-PNT/C-
Luc(Zeo) were plated at 40,000 cells/well in 96-well clear bottom black microplates (Corning 
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#6005182) and incubated overnight at 37 °C. Compound plates were thawed and compounds were 
added to cells using a BioRobotics BioGrid Robot Microarrayer Model equipped with a 96-pin 
tool with either 0.7 mm or 0.4 mm diameter pins. After a 4 h incubation at 37 °C, a 1:1 ratio of 
NanoFuel GLOW Assay reagent was added to the cells and plates were incubated in the dark at 
ambient room temperature for 15 min. Luminescence output was then read with a Varioskan LUX 
multimode or BioTek Neo 2 microplate reader.  
 
Secondary PCA 
Compounds that yielded a lower luminescence in the initial PCA screens were re-tested at 
different concentrations against cells stably expressing the split luciferases fused to ETV6 PNT 
domains or leucine zippers. The latter served as a specificity control. Cells were seeded at 40,000 
cells per well in 96-well plates and incubated at 37 °C overnight. The selected compounds were 
added to wells in duplicate at final concentrations of 1, 3, 10 and 30 µM. After 4 h incubation, 
cells were examined through a microscope for the presence of rounded, detached or dead cells, or 
for compound precipitates (Supplemental Fig. S1 for examples). Luminescence was read as 
previously described. 
 
Yeast Two-hybrid Assay Development  
The two-hybrid assay consists of bait and prey plasmids and a yeast reporter strain, 
constructed for this study. The bait plasmids expressed, from a constitutive ADH1 promoter, the 
Oct1 POU DNA-binding domain alone (pIS341) or a fusion between the Oct1 POU DNA-binding 
domain and the A93D-PNT domain (pIS586). They are ARS-CEN (single copy) plasmids with a 
TRP1 marker. The prey plasmids expressed the NLS-B42 activation domain (AD) alone (pIS580) 
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or a fusion between the AD and V112E-PNT domain (pIS591). These genes are under control of 
an inducible GAL1 promoter on 2 micron (multicopy) plasmids with a LEU2 marker.  
 Saccharomyces cerevisiae strain ISY361 was constructed from strain W303. It contains 
two integrated reporter genes. The HIS3 reporter with a minimal core promoter was integrated at 
an ade8 disruption with plasmid pIS452.27 The lacZ reporter was integrated at a lys2 disruption 
with pIS341.27 The expression of the two reporter genes is controlled by 4 upstream POU binding 
sites. The genotype is MATα, ade2-1, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, 
lys2::POU ops-LACZ, ade8::POU ops-HIS3. 
ISY361 was transformed with bait plasmid pIS586 and prey plasmid pIS591 to generate 
the strain ISY361+/+ expressing POU-A93D bait and AD-V112E prey. A strain containing bait 
plasmid pIS586 and prey plasmid pIS580 lacking the V112E domain was also generated to serve 
as a control and is referred to as ISY361+/-. 
 
High-throughput Yeast Two-hybrid Screening 
Yeast media were prepared with reagents obtained from Becton Dickinson and Sunrise 
Science Products. Strains were grown overnight at 30 °C with agitation in Synthetic Complete 
(SC) medium lacking Leu and Trp and containing 2% glucose. Cells were harvested by 
centrifugation at 4,700 g for 5 min, pellets were rinsed twice with sterile distilled water and cells 
were suspended at OD595 0.01 in SC medium lacking Leu, Trp and His and containing 2% 
galactose instead of glucose. The suspension also contained 2 mM 3-amino-1,2,4-triazole, which 
is used to minimize the effect of basal expression of HIS3.28,29 Cell suspension (100 µL) was 
distributed to wells of sterile clear flat bottom polystyrene 96-well microplates (Costar # 3370) 
using a dispensing 8-channel pipettor. Eight wells were reserved for blanks. Chemicals were added 
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to each well using a Biorobotics Biogrid II robot equipped with either a 0.7 mm or 0.4 mm diameter 
96-pin tool. The yeast plates were incubated at 30 °C in a humidified chamber without agitation 
for 48 h. The cells were suspended by gently vortexing for 1 min and OD595 readings were obtained 
using an Opsys MR 96-well plate reader (Dynex Technologies). OD595 readings of wells 
containing only medium were defined as 0% growth and OD595 readings of wells containing yeast 
but no screening chemicals were defined as 100% growth. 
The compounds were tested at either a final concentration of 10 or 15 µM. Compounds 
showing growth inhibition were typically re-tested at two different concentrations in duplicate in 
medium lacking His and in medium containing 20 µg/mL L-His. Compounds showing more 
growth inhibition in medium lacking His than in medium containing His were re-tested in two or 
more replicates over a concentration range. 
 
BUDE Virtual Screening  
Virtual ligand screening was carried out on the University of Bristol’s high performance 
computing system BlueCrystal with the docking program BUDE (Version 1.2.9)25 utilizing the 
University of California San Francisco ZINC8 virtual ligand database.30 Coordinates of monomer 
subunits were taken from the X-ray crystallographic structure of the polymeric ETV6T PNT 
domain (PDB: 1LKY) and used as representative of the wild-type interfaces in the A93D-PNT or 
V112R-PNT domain backgrounds. In brief, the protein structure, known as the receptor, was 
placed as a mol2 file with the origin at the wild-type A93 or V112 residue for the V112R- or 
A93D-PNT domain, respectively. Centered on the origin, the docking grid search volume was a 
15 Å x 15 Å x 15 Å cube. Members of the ZINC8 library, consisting of greater than 8 million 
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ligands (each having approximately 20 conformers per ligand generated), were tested for docking 
around the origin.  
A second BUDE screen with residues of the intermolecular K99-D101 salt bridge set as 
the origins. In addition, an ensemble of 10 different structures, obtained from 10 ns steps of a 100 
ns molecular dynamic (MD) simulation performed with GROMACS,31 were used as the receptors. 
Docking was carried out using the top 200,000 compounds, and their conformers, that exhibited 
the lowest binding energies in the first BUDE screen, described above.  
 
Molecular Dynamics Simulations on Docked Candidates  
Ligands that were targeted for the interfacial residues of the ETV6 PNT domain were 
ranked on their predicted free energy of binding. The top 500 compounds to each interface 
underwent a short 10 ns MD simulation of the ligand-protein complex to determine if they 
maintained a stable interaction. In brief the MD simulations were performed with AMBER 
(Version 16)32 using the FF14SB-ildn forcefield, TIP3P water and ligand parameters taken from 
the GAFF (General Amber Force Field).33 The full 10 ns simulations were run with 2 fs integration 
step size while maintaining a temperature of 300 K and pressure of 1 bar. Resulting ligand root-
mean-squared deviation (RMSD) time courses were calculated for the trajectories relative to the 
initial, midpoint and final poses using CPPTRAJ.34 In addition, the trajectories were visualized 
using VMD (Version 1.9.2) software.35 
 
BUDE Candidate Selection and Testing 
Compounds identified by virtual docking underwent several iterations of selection. First, 
the top ranked poses with the lowest calculated binding energies were manually inspected in 
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Chimera (Version 1.13.1).36 For the ligands targeted to the interface, those that had duplicate 
conformers with low RMSDs during 10 ns MD simulations were preferentially selected over those 
with high RMSDs or that dissociated. The generated list of potential compounds was further 
refined by considering their commercial availability and selected to give a range of chemical 
diversity targeting the EH or ML surfaces of the ETV6 PNT domain. In total, 50 compounds were 
purchased to target the core interfacial residues. Of these, 16 targeted the ML surface around A93 
in the V112E-PNT domain structure, 32 targeted the EH surface around V112 in the A93D-PNT 
domain structure, and 2 targeted both. In addition, 10 compounds were purchased to target the 
K99-D101 salt bridge (6 targeted D101 and 4 targeted K99). 
 
Testing of Compound Binding by NMR Spectroscopy 
Candidate compounds were tested in vitro for binding to the 15N-labeled PNT domain via 
15N-HSQC monitored titrations recorded at 25 °C with Bruker Avance 500 or 600 MHz 
spectrometers. Isotopically labeled ETV643-125 with either an A93D or V112E substitution was 
expressed in Escherichia coli and purified as described previously.19 Purchased compounds were 
dissolved to 50 mM stock solutions in DMSO. Purified protein samples were at a final 
concentration of 150 µM and volume of 450 µL in a standard buffer (20 mM MOPS, 50 mM NaCl, 
and 0.5 mM EDTA at pH 7.0 for A93D-PNT domain and pH 8.0 for V112E-PNT domain) with 
D2O (5% v/v) added for signal locking. All compounds were tested at a minimum of 2:1 molar 
ratio a maximum of 20:1 molar ratio compound to protein. Control titrations with DMSO were 




Development of a PCA to Screen for Inhibitors of PNT Domain Association 
Initially, we established and characterized a PCA for monitoring heterodimerization of the 
A93D- and V112E-PNT domains based on the split Gaussia luciferase methodology.23 Various 
fusion proteins containing the mutant ETV6 PNT domains and either N-Luc or C-Luc fragments 
were transiently expressed in HEK293 cells (Supplemental Table S2). Cell culture medium alone 
or cells exposed to the reagents needed for the transient transfections showed luminescence 
readings of 19 ± 2.4 (mean ± std. dev.) on a Varioskan LUX multimode microplate reader. When 
expressed alone, V112E-PNT/C-Luc, A93D-PNT/C-Luc and A93D-PNT/N-Luc also produced 
relatively low luminescence readings of ~ 600, either 48 or 72 h post-transfection. Co-expressing 
A93D- and V112E-PNT domains that can heterodimerize, but fused to the same luciferase 
fragment, also resulted in a low luminescence reading of 70 ± 59. Introduction of the 
complementary N-Luc and C-Luc luciferase fragments, each linked to the A93D-PNT domain 
yielded a higher luminescence of 2,500 ± 170. However, this was still low when compared to 
combinations of A93D-PNT/C-Luc and V112E-PNT/N-Luc or A93D-PNT/N-Luc and V112E-
PNT/C-Luc, that showed readings 48 h post-transfection of 320,000 ± 2,500 and 91,000 ± 17,000, 
respectively. The luminescence readings of these combinations diminished 72 h post-transfection. 
The higher luminescence readings of the A93D-PNT/C-Luc and V112E-PNT/N-Luc combination 
compared with the reciprocal combination may indicate that one orientation of the luciferase 
fragments is more favorable to reconstitution of the active enzyme than the other. Based on these 
initial studies, the constructs encoding A93D-PNT/C-Luc and V112E-PNT/N-Luc were expressed 
stably in HEK293 cells to facilitate high-throughput screening. 
There are no known inhibitors of ETV6 PNT domain polymerization to use as controls. 
However, the isolated PNT domain has a dominant-negative effect on cells expressing EN, 
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reverting morphology back to wild-type.19 Thus, we transiently transfected the A93D-PNT domain 
into the stably expressing HEK293 cells to test for an expected reduction in the luminescence 
reading due to competition with the A93D-PNT/N-Luc for the V112E-PNT/C-Luc binding 
interface (Fig. 2A). At 24 h post-transfection, the A93D-PNT domain caused a significant decrease 
in luminescence with this cell line, but not with control cells expressing luciferase fragments fused 
with leucine zippers. At 48 h post-transfection, both systems were affected, but the decrease was 
most pronounced with the cells for the PNT domain PCA. To a much lesser extent, a transiently 
transfected empty pcDNA3.1 vector also reduced luminescence for the two systems 48 h post-
transfection. Collectively, these controls define the expected sensitivity to inhibition of PNT 
domain heterodimerization.  
 
High-throughput Screening using the PNT Domain PCA 
In total, ~ 18,000 compounds were screened with the PNT domain PCA assay. Plates were 
analyzed individually due to the limited stability of the luminescence signal over time. Thresholds 
for hit identification are generally expressed in terms of standard deviations from the mean and 
can be set empirically based on the number of compounds from the library that can be reasonably 
screened in secondary assays.37 Thus, for this assay, compounds of interest were identified as 
having a luminescence reading that was more than two standard deviations away from the average 
luminescence reading of a plate (Fig. 3A), leading to an overall ~ 1 % hit rate. Statistical analysis 
of 146 plates screened, which encompasses all plates that were run that contained controls (not all 
plates had controls due to some drug screening plates allocating no space), comparing the positive 
control (the PNT domain PCA) and negative control (media), gave an overall Z’-factor for the 
screening assay of 0.33.37 However, due to the variation of the luminescence signal over time, 
 15 
calculating the Z’-factor per batch (i.e. per set of plates run at one time) resulted in a higher Z’-
factor of 0.71 ± 0.12 (n=17 batches). Furthermore, on a plate-by-plate analysis, the Z’ factor 
increased to 0.86 ± 0.07.   
Secondary testing of screening hits was performed in the PNT domain PCA and the control 
leucine zipper PCA systems (Fig. 3B). Compounds were re-tested in duplicates at 1, 3, 10 and 30 
µM, and every well was examined under the microscope. All compounds showing evidence of 
precipitation or obvious cell toxicity, demonstrated through cell rounding or death, were excluded 
for further validation. Out of 179 compounds retested, 83 did not decrease the luminescence in a 
concentration-dependent manner and were likely artifacts of the initial screens. All 96 of the 
remaining compounds that showed a concentration-dependent decrease of luminescence in the 
PNT domain PCA exhibited the same pattern with the leucine zipper PCA. Thus, changes in 
luminescence were likely due to factors other than inhibition of the PNT domain association. 
In addition to the secondary cellular screening, 13 of the 96 compounds were purchased 
and tested for binding in vitro to the PNT domain using NMR spectroscopy. These compounds 
were chosen as they had exhibited a concentration-dependent response in the PNT domain PCA 
prior to the leucine zipper PCA counter screen, and were commercially available. The 15N-HSQC 
spectra of 15N-labelled A93D-ETV643-125 was recorded upon progressive titration with each 
compound. Amide 1HN and 15N chemical shifts are highly sensitive to even subtle structural 
changes accompanying ligand binding.38 In no case were any chemical shift perturbations 
observed, indicating no detectable binding (Supplemental Table S3). 
 
Development of a Yeast Two-hybrid Assay to Screen for Inhibitors of PNT Domain Association  
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The yeast two-hybrid assay involved several plasmids in auxotrophic yeast strains (Fig. 
1B). The bait plasmid pIS586 encoded a fusion between the POU DNA-binding domain and the 
A93D-PNT domain, the prey pIS591 encoded a fusion between the NLS-B42 activation domain 
and the V112E-PNT domain, and the prey control pIS580 lacked the PNT domain. To validate the 
assay, we showed that the yeast strain ISY361+/+ containing the “bait + prey” plasmids indeed 
grew in the absence of His in the medium, whereas the “bait + control” strain ISY361+/- lacking 
the V112E-PNT domain showed little to no growth (Fig. 2B). Growth was restored upon addition 
of His to the latter, indicating that lack of growth was specifically due to lack of HIS3 gene 
expression. 
 
High-throughput Screening using the Yeast Two-hybrid Assay 
The compounds from the PoPPI, Sigma, BioMOL, Selleck, Prestwick, and Microsource 
libraries were screened in the yeast two-hybrid assay. The effects of the compounds on yeast cell 
growth were displayed as histograms for each library, with representative examples in Fig. 4A. In 
general, the libraries showed a narrow growth distribution range, with most compounds affecting 
growth by less than 10%. The 214 compounds from the Sigma, BioMOL, Selleck, Prestwick and 
Microsource libraries that showed > 50% growth inhibition were selected for secondary screening. 
No compound from the PoPPI library caused > 50% growth inhibition. Instead, the 21 compounds 
that showed > 20% growth inhibition in the PoPPI library were selected. Z’-factor calculation was 
carried out on each plate with the cells without addition of compound acting as positive controls 
and media as negative controls. The average Z’-factor was 0.67 ± 0.29 (n= 66 plates).  
Secondary screening was carried out using multiple concentrations of the hits from the 
primary screen. Several compounds, such as tannic acid (Fig. 4B) and acivicin (Fig. 4C), showed 
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a decrease of cell growth in the “bait + prey” strain that could be restored with addition of histidine 
and exhibited no decreased cell growth in the “bait + control” strain. It was subsequently 
recognized that acivicin is a glutamine analogue and can inhibit γ-glutamyltransferase,39 which is 
needed for histidine biosynthesis. While such compounds are false positives of the two-hybrid 
screen, they do validate that a growth response should be observed if a compound interferes with 
histidine biosynthesis through inhibition of PNT domain association.  
In total, three compounds (paromomycin, tannic acid, sanguinarine) caused a decrease in 
cell growth while having no reported impact on the biosynthesis of histidine. Thus, they were 
purchased for final testing utilizing NMR spectroscopy. NMR-monitored titrations were carried 
out with both 15N-labelled A93D- and V112E-ETV643-125. In all cases, no amide 1NH-15N chemical 
shift perturbations we observed, indicating that the three compounds do not detectably bind to the 
monomeric PNT domains in vitro (Supplemental Table S3). The reasons underlying their effects 
on the yeast two-hybrid screen are currently unknown. 
 
Virtual Screening for Inhibitors of ETV6 PNT Domain Self-Association 
Having found no inhibitors in the cell-based screening assays, we decided to perform 
virtual screening. Virtual screening for ligands predicted to bind the ETV6 PNT domain self-
association interfaces was performed using the BUDE algorithm with a high-performance 
computer cluster. Over 160 million total poses of ~ 8 million ligands from the ZINC8 library, 
averaging 20 conformers per molecule, were tested. Virtual docking of these molecules was 
initially directed towards 15 Å x 15 Å x 15 Å search boxes centered on the A93 and V112 
interfacial regions of the PNT domain (Fig. 5).  
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After running BUDE targeted to each PNT domain hydrophobic interface, the top 500 
compounds predicted to have the best binding energies were selected for short MD simulations. 
The simulations were carried out to determine if the compounds would theoretically remain 
associated with the PNT domain over a 10 ns sampling. The coordinate RMSDs of each ligand 
throughout the simulation versus its initial, midpoint (5 ns) and endpoint (10 ns) pose were plotted. 
Based on these RMSD plots, ligands were scored as “excellent”, “good”, “mediocre” and “bad” 
(Fig. 6). For the A93D PNT domain, 33 and 101 compounds were deemed excellent and good, 
respectively, and the V112E PNT domain had 42 and 73 compounds were deemed excellent and 
good, respectively. In parallel, every compound in the top 500 was visually analyzed for common 
structural motifs and suitable interactions. 
Compounds selected for testing by NMR spectroscopy and the screening assays had 
excellent or good scores in MD simulations, appeared to interact closely with the PNT domain, 
were commercially available and represented a range of chemical motifs to increase diversity. 
Preference was given to compounds that were predicted to bind in multiple conformers. Several 
additional compounds that had a BUDE ranking > 500 were also selected due to possessing certain 
structural motifs, such as carboxylates or protonated amines, that could potentially interact with 
complementary motifs of the PNT domain. Collectively, this resulted in 35 and 17 compounds 
predicted to bind the hydrophobic interfaces centered around A93 (ML surface) and V112 (EH 
surface) of the V112E- or A93D-PNT domain monomers, respectively (Supplemental Fig. S2). 
 A second screening was subsequently carried out to target the interfaces around K99 and 
D101. These residues form an intermolecular salt bridge (Fig. 5). Furthermore, to help account for 
protein dynamics, an ensemble of protein structures taken at 10 ns steps of 100 ns MD simulations 
were used for docking. To accelerate the process, we also focused on only the top 200,000 
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compounds from the first BUDE screen and their respective conformers. In total, ~ 4 million poses 
of ligands were tested for docking to the 10 different A93D- or V112E-PNT domain structures. 
The resulting top 500 candidates were visually inspected and 10 compounds with chemical 
diversity were selected for testing (Supplemental Fig. S3). 
 
Experimental Testing of the Virtual Screening 
A total of 60 candidate compounds from two BUDE screens were purchased for further 
testing. All compounds were used for NMR-monitored titrations with samples of 15N-labelled 
A93D- or V112E-ETV643-125, as appropriate. None were found to bind with any detectable affinity 
as evidenced by the lack of amide 1NH-15N chemical shift perturbations (Fig. 7A and Supplemental 
Table S3). In parallel, the compounds were screened in both the yeast two-hybrid and the 
mammalian cell assays. No compounds were growth inhibitory in the yeast assay, and in the PNT 
domain PCA, one compound was identified as a screening hit (Fig. 7B). However, this compound 
also demonstrated reduced luminescence in the leucine zipper PCA, possibly inhibiting luciferase 
or other confounding factors related to cellular proliferation. Despite extensive efforts, virtual 




In this study, we established three complementary approaches to screen for potential 
inhibitors of ETV6 PNT domain polymerization. Unfortunately, we did not succeed in discovering 
any small molecules that bound the PNT domain in vitro or disrupted its self-association in vivo. 
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Nevertheless, valuable insights were gained that should facilitate future studies aimed at 
modulating protein-protein interactions with systems similar to ETV6. 
The mammalian and yeast cell assays were designed for unbiased high-throughput 
screening of compounds in a cellular context, with a readout that is dependent upon disruption of 
a heterodimer model of the ETV6 polymer. However, in the PCA assay, screening hits can arise 
not only from inhibition of heterodimerization, but also from perturbation of split luciferase 
reconstitution or luciferase activity, as well as due to cytotoxicity or inhibition of cellular 
proliferation. Therefore, the leucine zipper PCA was critical as a control assay to determine 
whether any reduction in luminescence was due to the latter confounding effects. Similarly, in the 
yeast screening assay, the use of a control vector and addition of histidine to secondary testing of 
screening hits for growth rescue were used to eliminate any compounds that caused cell death or 
inhibition of the histidine biosynthetic pathway. 
It is worth emphasizing that the ETV6 A93D- and V112E-PNT domains heterodimerize 
with low nM affinity.18,19 This certainly presents a challenge in discovering potentially rare 
compounds in chemical libraries with comparable affinities to effectively disrupt this tight protein-
protein interaction. A mitigating strategy might involve the initial use of PNT domain variants 
with additional mutations to weaken their association and thereby reduce the stringency of the 
assay. Such variants may be inspired by detailed biophysical analyses of the ETV6 PNT domain 
interfaces.40 In addition, it would be beneficial to use cell-based “up” assays that positively select 
for disruption of PNT domain association or employ a readout that increases, rather than decreases, 
with this result.  
To this end, we explored use of a yeast two-hybrid assay where expression of HIS3 and 
LacZ reporter genes are dependent upon PNT domain heterodimerization. However, this assay as 
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implemented was not useful for discovery of inhibitors because potential hits in small molecule 
screens would prevent growth on medium lacking His, and loss of LacZ expression, which could 
also be produced by various alternative effects unrelated to inhibition of the PNT domain 
interaction. Ideally, the screening assay could be modified to include a reporter such as CAN1 or 
URA3, where inhibitors of the interaction would prevent activation, allowing detection by growth 
on canavanine or 5-fluoroorotic acid, respectively.41 Alternatively, yeast-based strategies could 
also be used such as the repressed transactivator system, where interaction of bait and prey fusions 
cause repression of gene expression, and inhibitors of the interaction cause gene activation, which 
is detected by growth of yeast on selective media.42 However, this system is currently limited to 
use with Gal4 DNA-binding domain fusions, and we were unable to detect interaction of PNT 
fusions in yeast using the Gal4 DNA-binding domain linked to the PNT domain.  
In parallel to cellular assays, we undertook a targeted virtual screening approach to search 
for compounds that bind the known polymerization interfaces of the ETV6 PNT domain. Although 
BUDE has been successful in identifying inhibitors of PPIs,26 and numerous potential ligands were 
predicted to bind the ETV6 PNT domain in silico, none were found to do so when tested in vitro 
with NMR spectroscopy or in vivo with cellular assays. However, common motifs that were 
enriched may serve as starting structures for rational design or further high-throughput screening 
experiments.  
We recognize that this target is particularly challenging since the ETV6 PNT domain 
polymerizes with high affinity through two relatively large flat interfaces. These comprise 
complementary central hydrophobic patches ringed by hydrophilic and charged residues with 
relatively flexible sidechains. Tightly bound ligands typically occupy depressions or cavities on 
the protein surface, but these features are absent with the PNT domain. However, in the case of 
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targeting the intermolecular salt-bridge, the virtual ligands seemed to be predicted to preferentially 
bind to certain PNT domain structures taken from short MD simulations. This flexibility of the 
protein may expose conformations better suited for small molecule interactions.  
It is unfortunate that some of the best hits from the virtual screen were not commercially 
available. Experimental testing of these compounds, as well as more in silico hits, might yield 
success. Indeed, a “similarity paradox” has been described where minor chemical modifications 
of otherwise similar molecules can render them active or inactive.43 This paradox may suggest 
that, in our efforts to test a diverse set of compounds that sampled chemical space, we missed a 
high-ranking compound with affinity for the ETV6 PNT domain. Such a large-scale screening 
approach may be effective, as many protein-protein interaction inhibitors are found through 
traditional cellular screening only after screening in excess of hundreds of thousands of compounds 
and carrying out structure-activity relationship studies to optimize initially detected weak-binding 
leads.44  
Fragment-based drug design and disulfide tethering, combined with combinatorial 
chemistry, are two approaches that could also be undertaken as the next steps in developing an 
inhibitor against PNT domain polymerization.45–47 Inspiration can also be found in the design of 
cyclic peptides and helix peptide mimetics that weakly bind the SAM domains of the Ship2 and 
EphA2 receptors.48,49 In all cases, virtual screening could be used to narrow down potential 
chemical motifs of interest for a more targeted screening approach. Collectively, such a multi-
pronged strategy may lead to the discovery of a potentially new class of therapeutics that prevent 
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 Figure Legends 
 
Figure 1. (A) The general principle behind the split-luciferase PCA. When the A93D- and V112E-
PNT domains heterodimerize (left), the split luciferase fragments assemble into an active enzyme 
which, upon addition of substrate, generates a luminescence output. If a small molecule (star) 
disrupts the interaction (right), either by directly binding the interface or by inducing an allosteric 
conformation change, then the equilibrium shifts away from reconstitution of the luciferase 
fragments, resulting in reduced luminescence. (B) In the yeast two-hybrid approach, the PNT 
domains are covalently linked to either a POU DNA-binding domain (DBD) or an activating 
domain (AD). Heterodimerization induces expression of the HIS3 gene to allow cell growth in 
medium lacking His (left). If a small molecule disrupts the interaction (right), there is no 
expression of the HIS3 gene and no yeast growth. Addition of His to the medium enables yeast 
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growth in the absence or presence of an inhibitor of the PNT domain interaction or the histidine 
biosynthetic pathway. These cartoons are highly schematic, especially with respect to the folding 
of the luciferase fragments. 
 
Figure 2. (A) The A93D-PNT domain-expressing and empty pcDNA3.1 vectors were transiently 
transfected into the PCA systems with luciferase fragments fused to either complementary PNT 
domains or leucine zippers. Controls with only transfection reagents were also run in parallel. 
Luminescence readings were normalized to untreated PNT domain or leucine zipper PCAs cells, 
respectively, with means and standard deviations of the 3 replicates. One-way ANOVA statistical 
analyses were performed and the calculated P values are given above the horizontal bars. (B) Yeast 
growth as detected by OD595. Co-expression of the bait (A93D-PNT Domain/POU DBD) + prey 
(V112E-PNT domain/AD) plasmids enables ISY361+/+ yeast growth with (light purple) and 
without (dark purple) addition of His. In contrast, without added His, no growth was seen for 
ISY361+/- yeast containing the bait plasmid and an empty control plasmid that lacks the 
complementary PNT domain. Each condition was replicated 5 times.  
 
Figure 3. (A) Shown are the results of the PNT domain PCA with compound plates from the 
Prestwick (335, 338, 339), Biomol (342), Sigma (348, 355) and Microsource (368) libraries. The 
circles represent the luminescence reading of each well of a 96-well plate. The red bars represent 
the mean relative luminescence and standard deviation of that plate. Pink circles represent wells 
that were exposed to only DMSO. An initial screening hit is defined as being more than two 
standard deviations away from the mean (blue circles) (B) Compounds identified as hits in the 
initial high-throughput screen were retested for a concentration-dependent response in the PNT 
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domain and leucine zipper PCAs. Compounds were tested in duplicate at 1, 3, 10 and 30 µM and 
cells were visually examined to determine toxicity or compound precipitation. Those that were not 
cytotoxic and elicited a similar response in the both PCA systems, were likely inhibitors of split-
luciferase reconstitution, luciferase activity itself or another variable. Compounds 1-2 represent 
examples of artifacts of the original, large-scale screen whereas compounds 3-5 represent 
examples of concentration-dependent responses. Compound 1: (±)-pindobind; Compound 2: 
gitoxigenin diacetate; Compound 3: rosolic acid; Compound 4: gambogic acid amide; Compound 
5: 3,4-dimethoxydalbergione. 
 
Figure 4. (A) Shown are two compound libraries that were tested in the yeast two-hybrid assay 
with ISY361+/+ co-expressing bait (A93D-PNT Domain/POU DBD) and prey (V112E-PNT 
domain/AD) plasmids. The histograms summarize the number of compounds versus growth of 
untreated cells, defined as 100%. Compounds causing reduced growth were subsequently carried 
on to secondary testing. Both tannic acid (B) and acivicin (C) showed concentration-dependent 
inhibition of the growth of yeast containing the “bait + prey” plasmids. This could be rescued 
through addition of His, indicating that neither compound is toxic to the cells. A similar pattern 
was seen with ISY361+/- yeast harboring the “bait + control” plasmids, whereby His rescues the 
cell growth in absence of a functioning HIS3 gene. Acivicin was later found to be an inhibitor of 
γ-glutamyltransferase which is necessary for histidine synthesis.  
 
Figure 5. General overview of the BUDE screening. The origin for the starting position of the 
ligand in the virtual screen is indicated by the grey sphere and the search space was centered around 
this point. To target the hydrophobic interfaces (upper), PNT domain structures were taken from 
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(PDB: 1lKY). To target the flanking salt bridge (lower), 10 structures from a 100 ns molecular 
dynamics simulation were chosen.  
 
Figure 6. Coordinates of selected ligands over the course of 10 ns MD simulations were compared 
to the starting (red), midpoint (purple) and endpoint (blue). Ligands were deemed as "excellent" 
(low RMSDs), "good" (RMSDs < 10 Å), "mediocre" (RMSDs > 10 Å) or "bad" (RMSDs > 30 Å, 
indicating dissociation). 
 
Figure 7. (A) Shown are overlaid 15N-HSQC spectra of the 15N-labelled A93D-ETV643-125 in the 
absence (blue) and presence of a 5:1 molar ratio (orange) of a BUDE screening hit MolPort-005-
035-860 (top), and the 15N-labelled V112E-ETV643-125 in the absence (green) and presence of a 
3:1 molar ratio (orange) of a BUDE screening hit MolPort-004-826-786 (bottom). The lack of any 
amide chemical shift perturbations indicated no detectable binding. (B) Luminescence readings of 
60 compounds, identified through the BUDE virtual screens, tested with the mammalian cell split 
luciferase assay. One compound (MolPort-005-970-014; blue star), reduced luminescence in both 
the PNT domain and leucine zipper PCAs. The lower signals relative to previously presented 
studies is due to the use of a BioTek Neo 2 plate reader. 
 
 







